In a report published Monday, J.P. Morgan analyst Chris Schott reiterated an Overweight rating and $39.00 price target on Zoetis ZTS.
In the report, J.P. Morgan noted, “Following the Pfizer share exchange making Zoetis a fully publicly-owned company, we wanted to revisit our thesis on the stock. Overall, the exchange does not alter our view on the company or the stock and we see Zoetis as a fairly unique asset within the healthcare space with a highly diversified portfolio, a significant emerging markets presence, and lack of third-party payer or generic exposure. Zoetis remains a clear leader within its industry and we believe the company is capable of generating sustainable mid-single digit top-line growth and low to mid-teens EPS growth. ZTS shares remain OW rated with a $39 price target.”
Zoetis closed on Friday at $30.17.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.